Embecta Corp.

NasdaqGS EMBC

Embecta Corp. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -73.40 M

Embecta Corp. Net Cash Used Provided By Financing Activities is USD -73.40 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -50.72% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Embecta Corp. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -48.70 M, a -1.46% change year over year.
Embecta Corp. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -48.00 M, a 88.49% change year over year.
Embecta Corp. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -417.00 M.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

NasdaqGS: EMBC

Embecta Corp.

CEO	Mr. Devdatt Kurdikar
IPO Date	March 22, 2022
Location	United States
Headquarters	300 Kimball Drive
Employees	2,200
Sector	Health Care
Industries Medical Instruments Pharmaceuticals

Description

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Key trends

Past 5 years